Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 10, 2013, Pages 1745-1755

  Schröder, Christine ^a   Milde Langosch, Karin ^a   Gebauer, Florian ^a   Schmid, Katharina ^a   Mueller, Volkmar ^a   Wirtz, Ralph M ^b   Meyer Schwesinger, Catherine ^a   Schlüter, Hartmut ^a   Sauter, Guido ^a   Schumacher, Udo ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b STRATIFYER Molecular Pathology GmbH   (Germany)

Author keywords

Breast cancer; Microarray analysis; Prognosis; TMA; UCH L1

Indexed keywords

ESTROGEN RECEPTOR; HYDROLASE; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR MARKER; UCH L1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GERMANY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UCH L1 GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; UBIQUITIN THIOLESTERASE;

EID: 84884669126     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1496-z     Document Type: Article

References (36)

1. Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y, Hirohashi S (2010) Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol 134(1):71-79. doi: 10.1309/AJCPRJP39MIDSGBH
2. Doran JF, Jackson P, Kynoch PA, Thompson RJ (1983) Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis. J Neurochem 40(6):1542-1547
3. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
4. Fang Y, Fu D, Shen XZ (2010) The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 1:1-6. doi: 10.1016/j.bbcan. 2010.03.001
5. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456-1466
6. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100(2):237-238. doi: 10.1007/s10549-006-9253-5
7. Hurst-Kennedy J, Chin LS, Li L (2012) Ubiquitin C-terminal hydrolase l1 in tumorigenesis. Biochem Res Int 2012:123706. doi: 10.1155/2012/123706
8. Hussain S, Foreman O, Perkins SL, Witzig TE, Miles RR, van Deursen J, Galardy PJ (2010) The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 24(9):1641-1655. doi: 10.1038/leu.2010.138
9. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, Nishiyama K, Seki N, Nakagawa M (2008) CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 180(1):343-351. doi: 10.1016/j.juro.2008.02.044
10. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Lee KJ (2009) Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 28(1):117-127. doi: 10.1038/onc.2008.364
11. Larsen CN, Price JS, Wilkinson KD (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35(21):6735-6744. doi: 10.1021/bi960099f
12. Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37(10):3358-3368. doi: 10.1021/bi972274d
13. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67(16):1761-1769. doi: 10.1002/pros.20654
14. Liu X, Zeng B, Ma J, Wan C (2009) Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 27(3):345-352. doi: 10.1080/07357900802438577
15. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, Sidransky D (2005) PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65(11):4963-4968. doi: 10.1158/0008-5472. CAN-04-3923
16. Miyoshi Y, Nakayama S, Torikoshi Y, Tanaka S, Ishihara H, Taguchi T, Tamaki Y, Noguchi S (2006) High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 97(6):523-529. doi: 10.1111/j.1349-7006.2006.00202.x
17. National Cancer Institute. Surveillance Epidermiology and End Results (2008) http://www.seer.cancer.gov
18. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123(5):773-786. doi: 10.1016/j.cell.2005.11.007
19. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119(6):1338-1344. doi: 10.1002/ijc.22025
20. Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nemoto N, Shichino H, Chin M, Mugishima H, Suzuki T (2008) Useful markers for detecting minimal residual disease in cases of neuroblastoma. Biol Pharm Bull 31(6):1071-1074
21. Orr KS, Shi Z, Brown WM, O'Hagan KA, Lappin TR, Maxwell P, Percy MJ (2011) Potential prognostic marker ubiquitin carboxyl-terminal hydrolase-L1 does not predict patient survival in non-small cell lung carcinoma. J Exp Clin Cancer Res 30:79. doi: 10.1186/1756-9966-30-79
22. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, Wada K (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12(16):1945-1958
23. Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Tsujioka T, Sato Y, Murakami H, Sadahira Y, Sugihara T (2004) Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 127(3):292-298. doi: 10.1111/j.1365-2141.2004.05205.x
24. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138-140
25. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61(3):939-942
26. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118(9):2190-2194. doi: 10.1002/ijc.21581
27. Schumacher U, Mitchell BS, Kaiserling E (1994) The neuronal marker protein gene product 9.5 (PGP 9.5) is phenotypically expressed in human breast epithelium, in milk, and in benign and malignant breast tumors. DNA Cell Biol 13(8):839-843
28. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R (2007) Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 13(1):27-37. doi: 10.1158/1078-0432.CCR-06-0824
29. Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36(1):98-105
30. Tezel E, Hibi K, Nagasaka T, Nakao A (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6(12):4764-4767
31. Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J (1983) PGP 9.5-a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 278(1-2):224-228
32. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123(4):753-759. doi: 10.1002/ijc.23354
33. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246(4930):670-673
34. Wilkinson KD, Deshpande S, Larsen CN (1992) Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem Soc Trans 20(3):631-637
35. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, Mori M, Sidransky D (2006) PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66(7):3921-3927. doi: 10.1158/0008-5472.CAN-05-1511
36. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8(1):192-195